These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

712 related items for PubMed ID: 22584031

  • 21. Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study.
    Steuber T, Budäus L, Walz J, Zorn KC, Schlomm T, Chun F, Ahyai S, Fisch M, Sauter G, Huland H, Graefen M, Haese A.
    BJU Int; 2011 Jun; 107(11):1755-61. PubMed ID: 20942833
    [Abstract] [Full Text] [Related]

  • 22. Early detection of high-grade prostate cancer using digital rectal examination (DRE) in men with a prostate-specific antigen level of <2.5 ng/mL and the risk of death.
    Hattangadi JA, Chen MH, D'Amico AV.
    BJU Int; 2012 Dec; 110(11):1636-41. PubMed ID: 22757982
    [Abstract] [Full Text] [Related]

  • 23. Selecting men diagnosed with prostate cancer for active surveillance using a risk calculator: a prospective impact study.
    van Vugt HA, Roobol MJ, van der Poel HG, van Muilekom EH, Busstra M, Kil P, Oomens EH, Leliveld A, Bangma CH, Korfage I, Steyerberg EW.
    BJU Int; 2012 Jul; 110(2):180-7. PubMed ID: 22112199
    [Abstract] [Full Text] [Related]

  • 24. Single application of high-intensity focused ultrasound as a first-line therapy for clinically localized prostate cancer: 5-year outcomes.
    Pfeiffer D, Berger J, Gross AJ.
    BJU Int; 2012 Dec; 110(11):1702-7. PubMed ID: 22928703
    [Abstract] [Full Text] [Related]

  • 25. Preoperative serum testosterone level as an independent predictor of treatment failure following radical prostatectomy.
    Yamamoto S, Yonese J, Kawakami S, Ohkubo Y, Tatokoro M, Komai Y, Takeshita H, Ishikawa Y, Fukui I.
    Eur Urol; 2007 Sep; 52(3):696-701. PubMed ID: 17412490
    [Abstract] [Full Text] [Related]

  • 26. Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience.
    Soloway MS, Soloway CT, Williams S, Ayyathurai R, Kava B, Manoharan M.
    BJU Int; 2008 Jan; 101(2):165-9. PubMed ID: 17850361
    [Abstract] [Full Text] [Related]

  • 27. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.
    Auprich M, Augustin H, Budäus L, Kluth L, Mannweiler S, Shariat SF, Fisch M, Graefen M, Pummer K, Chun FK.
    BJU Int; 2012 Jun; 109(11):1627-35. PubMed ID: 21939492
    [Abstract] [Full Text] [Related]

  • 28. Unilateral positive biopsies in low risk prostate cancer patients diagnosed with extended transrectal ultrasound-guided biopsy schemes do not predict unilateral prostate cancer at radical prostatectomy.
    Gallina A, Maccagnano C, Suardi N, Capitanio U, Abdollah F, Raber M, Salonia A, Scattoni V, Rigatti P, Montorsi F, Briganti A.
    BJU Int; 2012 Jul; 110(2 Pt 2):E64-8. PubMed ID: 22093108
    [Abstract] [Full Text] [Related]

  • 29. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
    Faria EF, Carvalhal GF, dos Reis RB, Tobias-Machado M, Vieira RA, Reis LO, Nogueira L, Machado RD, Freitas CH, Magnabosco WJ, Mauad EC, Carvalho AL.
    BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
    [Abstract] [Full Text] [Related]

  • 30. Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer.
    Guazzoni G, Lazzeri M, Nava L, Lughezzani G, Larcher A, Scattoni V, Gadda GM, Bini V, Cestari A, Buffi NM, Freschi M, Rigatti P, Montorsi F.
    Eur Urol; 2012 Mar; 61(3):455-66. PubMed ID: 22078333
    [Abstract] [Full Text] [Related]

  • 31. Hormonal predictors of prostate cancer.
    Sofikerim M, Eskicorapci S, Oruç O, Ozen H.
    Urol Int; 2007 Mar; 79(1):13-8. PubMed ID: 17627161
    [Abstract] [Full Text] [Related]

  • 32. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
    Scholz M, Lam R, Strum S, Jennrich R, Johnson H, Trilling T.
    Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
    [Abstract] [Full Text] [Related]

  • 33. Serum total testosterone is a significant preoperative variable independently contributing to separating the prostate cancer population into prostatectomy Gleason score groups.
    Porcaro AB, Petrozziello A, Ghimenton C, Migliorini F, Sava T, Caruso B, Cocco C, Romano M, Cavalleri S, Artibani W.
    Urol Int; 2013 Sep; 91(1):55-61. PubMed ID: 23751412
    [Abstract] [Full Text] [Related]

  • 34. The relationship between total and free serum testosterone and the risk of prostate cancer and tumour aggressiveness.
    Morote J, Ramirez C, Gómez E, Planas J, Raventós CX, de Torres IM, Catalán R.
    BJU Int; 2009 Aug; 104(4):486-9. PubMed ID: 19220251
    [Abstract] [Full Text] [Related]

  • 35. Comprehensive analysis of post-diagnostic prostate-specific antigen kinetics as predictor of a prostate cancer progression in active surveillance patients.
    Iremashvili V, Manoharan M, Lokeshwar SD, Rosenberg DL, Pan D, Soloway MS.
    BJU Int; 2013 Mar; 111(3):396-403. PubMed ID: 22703025
    [Abstract] [Full Text] [Related]

  • 36. Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study.
    Marberger M, Freedland SJ, Andriole GL, Emberton M, Pettaway C, Montorsi F, Teloken C, Rittmaster RS, Somerville MC, Castro R.
    BJU Int; 2012 Apr; 109(8):1162-9. PubMed ID: 21699645
    [Abstract] [Full Text] [Related]

  • 37. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
    Teh BS, Ayala G, Aguilar L, Mai WY, Timme TL, Vlachaki MT, Miles B, Kadmon D, Wheeler T, Caillouet J, Davis M, Carpenter LS, Lu HH, Chiu JK, Woo SY, Thompson T, Aguilar-Cordova E, Butler EB.
    Int J Radiat Oncol Biol Phys; 2004 Apr 01; 58(5):1520-9. PubMed ID: 15050332
    [Abstract] [Full Text] [Related]

  • 38. Serum testosterone level as a predictor of biochemical failure after radical prostatectomy for localized prostate cancer.
    Røder MA, Christensen IJ, Berg KD, Gruschy L, Brasso K, Iversen P.
    BJU Int; 2012 Feb 01; 109(4):520-4. PubMed ID: 21851535
    [Abstract] [Full Text] [Related]

  • 39. Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of < or =10 ng/mL and biopsy Gleason score of < or =6, and their influence on PSA progression-free survival after radical prostatectomy.
    Weckermann D, Goppelt M, Dorn R, Wawroschek F, Harzmann R.
    BJU Int; 2006 Jun 01; 97(6):1173-8. PubMed ID: 16686707
    [Abstract] [Full Text] [Related]

  • 40. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
    Guazzoni G, Nava L, Lazzeri M, Scattoni V, Lughezzani G, Maccagnano C, Dorigatti F, Ceriotti F, Pontillo M, Bini V, Freschi M, Montorsi F, Rigatti P.
    Eur Urol; 2011 Aug 01; 60(2):214-22. PubMed ID: 21482022
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 36.